Abstract
Accumulating evidence indicates that low grade inflammation is closely associated with obesity-related disorders including type 2 diabetes, hypertension and atherosclerosis. Adiponectin is a fat-derived plasma protein with anti-inflammatory functions. Circulating levels of adiponectin are decreased in obese states, and these conditions are broadly associated with various obesity-related diseases. Furthermore, adiponectin has direct protective functions against cardiovascular disease, cerebrovascular disease, non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). In this review, we will focus on the protective functions of adiponectin against these obesity-related diseases from the view point of its anti-inflammatory properties.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adiponectin / metabolism*
-
Adiponectin / therapeutic use
-
Animals
-
Anti-Inflammatory Agents / therapeutic use
-
Cardiovascular Diseases / immunology
-
Cardiovascular Diseases / metabolism
-
Cardiovascular Diseases / prevention & control
-
Drug Design
-
Humans
-
Inflammation / immunology
-
Inflammation / metabolism*
-
Inflammation / prevention & control
-
Insulin Resistance
-
Molecular Targeted Therapy
-
Non-alcoholic Fatty Liver Disease / immunology
-
Non-alcoholic Fatty Liver Disease / metabolism
-
Non-alcoholic Fatty Liver Disease / prevention & control
-
Obesity / complications
-
Obesity / drug therapy
-
Obesity / immunology
-
Obesity / metabolism*
-
Protective Factors
-
Risk Factors
-
Signal Transduction
Substances
-
Adiponectin
-
Anti-Inflammatory Agents